RxDoctor Payments Data

Evan Li, MD

Allergy & Immunology · Houston, TXNPI 1427342906

Payments from drug & device makers

$1,777in general payments, 2019–2025

Across 37 payments — averaging $48.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$102
  • Blueprint Medicines Corporation$99
  • Sanofi-aventis U.S. LLC$77
  • Regeneron Healthcare Solutions, Inc.$66
  • Novartis$59
  • plus $311 from 8 others

What the payments were for

  • Consulting fees$73041%
  • Food & beverage$1,03258%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,777 in reported general payments places this provider in the 25th percentile of 336 allergy & immunology providers in Texas.

See all allergy & immunology providers in Texas

Medicare billing

Part B allowed, 2024
$31,014
Medicare patients
96
Services billed
1,306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HaegardaC1 Esterase Inhibitor12$344,381
Dupixent PenDupilumab46$203,916
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5026$179,047
XolairOmalizumab26$75,827
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$13,469
Epinephrine37$9,338
Cyclosporine12$7,018
SymbicortBudesonide/Formoterol Fumarate17$4,349
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$2,369
Azelastine Hcl38$1,332
Fluticasone Propionate57$964
Famotidine24$552
Montelukast Sodium13$398
Ipratropium Bromide12$351
Fluconazole21$265

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHaegarda$57$344,38112 claims
Takeda Pharmaceuticals U.S.A., Inc.Cuvitru$102$179,04726 claims
GSKTrelegy Ellipta$47$13,46920 claims
AstraZenecaSymbicort$42$4,34917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 336 allergy & immunology providers in Texas.

Other allergy & immunology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →